Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CYRUS M KHAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558576660
CMS profile
251650
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$320,569.94

343 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 343 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CYRUS M KHAN

NPI 1558576660 · CMS profile ID 251650

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 343 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558576660?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CYRUS M KHAN, NPI 1558576660, CMS profile ID 251650. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 343 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558576660?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CYRUS M KHAN, NPI 1558576660, CMS profile ID 251650. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 343 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558576660?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CYRUS M KHAN, NPI 1558576660, CMS profile ID 251650, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 343 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558576660?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

343 matching records · $320,569.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 343 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 343.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $19.7406/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152195 CMS
Pharmacyclics LLC, An AbbVie Company $3,800.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705933 CMS
Pharmacyclics LLC, An AbbVie Company $29.7606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705935 CMS
Pharmacyclics LLC, An AbbVie Company $3.6806/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705937 CMS
Pharmacyclics LLC, An AbbVie Company $1.5906/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705939 CMS
Pharmacyclics LLC, An AbbVie Company $158.3406/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705941 CMS
Pharmacyclics LLC, An AbbVie Company $15.5006/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705943 CMS
AstraZeneca Pharmaceuticals LP $4,450.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685129491 CMS
Aurobindo Pharma USA, Inc. $93.2606/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660459357 CMS
GENZYME CORPORATION $25.0006/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694041665 CMS
AbbVie, Inc. $4,025.0006/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152177 CMS
Genentech USA, Inc. $14.9406/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681251279 CMS
Genentech USA, Inc. $124.8006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681279339 CMS
Genentech USA, Inc. $1,107.4306/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295215 CMS
Genentech USA, Inc. $4,160.0006/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681317219 CMS
AbbVie, Inc. $69.7106/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152175 CMS
Kyowa Kirin, Inc. $606.7706/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687563167 CMS
Kyowa Kirin, Inc. $21.3306/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687563169 CMS
Pharmacyclics LLC, An AbbVie Company $61.6706/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705681 CMS
Pharmacyclics LLC, An AbbVie Company $3,800.0006/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705683 CMS
Pharmacyclics LLC, An AbbVie Company $95.7006/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705685 CMS
Takeda Pharmaceuticals U.S.A., Inc. $83.7906/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697375889 CMS
Takeda Pharmaceuticals U.S.A., Inc. $114.7006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697375899 CMS
AbbVie, Inc. $4,025.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152171 CMS
AbbVie, Inc. $334.6005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152157 CMS
AbbVie, Inc. $264.0005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152163 CMS
AbbVie, Inc. $349.9005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152169 CMS
AbbVie, Inc. $119.4605/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152179 CMS
Celgene Corporation $8.9905/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672840217 CMS
Celgene Corporation $2,625.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672840287 CMS
Celgene Corporation $1,092.6005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672840483 CMS
Celgene Corporation $139.3305/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672849801 CMS
Celgene Corporation $61.8005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672852675 CMS
Celgene Corporation $189.1305/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672852729 CMS
Celgene Corporation $3,850.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672855189 CMS
Takeda Pharmaceuticals U.S.A., Inc. $710.9005/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697375885 CMS
AstraZeneca Pharmaceuticals LP $24.9705/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685309867 CMS
AstraZeneca Pharmaceuticals LP $85.1705/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685333329 CMS
AstraZeneca Pharmaceuticals LP $1,090.3705/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685798551 CMS
Genentech USA, Inc. $550.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681207643 CMS
Janssen Biotech, Inc. $3,800.0005/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658523235 CMS
AbbVie, Inc. $6.2805/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648152159 CMS
Genentech USA, Inc. $237.2205/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681150675 CMS
Genentech USA, Inc. $4,160.0005/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681153619 CMS
Genentech USA, Inc. $1,971.2305/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681214853 CMS
Genentech USA, Inc. $73.9605/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681310547 CMS
Janssen Biotech, Inc. $1,364.9605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658523205 CMS
Janssen Biotech, Inc. $122.0405/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658523209 CMS
Janssen Biotech, Inc. $6.2805/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658523213 CMS
Kyowa Kirin, Inc. $460.6005/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687563151 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $320,569.94 343
PY2020 $198,032.76 163
PY2021 $224,818.23 203
PY2022 $322,642.88 255
PY2023 $340,365.01 304
PY2024 $238,606.64 234
PY2025 $268,798.16 252

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $535.60 2
PY2025 Principal investigator $329,880.73 62
PY2024 Recipient $3,012.60 4
PY2024 Principal investigator $238,916.49 87
PY2023 Principal investigator $333,820.57 72
PY2022 Recipient $2,026.05 1
PY2022 Principal investigator $446,032.18 30
PY2021 Principal investigator $200,394.17 19
PY2020 Principal investigator $871,418.30 35
PY2019 Principal investigator $149,215.72 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Epizyme, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285170
Principal investigator 1 Epizyme, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285172
Principal investigator 1 Epizyme, Inc. $800.00 12/23/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285174
Principal investigator 1 Genentech, Inc. $1,750.00 12/18/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571311
Principal investigator 1 Genentech, Inc. $5,658.00 12/04/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571396
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,000.00 12/03/2025 Non-covered Recipient Entity
Allegheny-singer Research Institute (asri)
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1235999143
Principal investigator 1 Epizyme, Inc. $1,011.86 11/28/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285168
Principal investigator 1 Genentech, Inc. $17,854.00 11/20/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571391
Principal investigator 1 Genentech, Inc. $400.00 11/17/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571387
Principal investigator 1 BeOne Medicines Ltd. $1,600.00 10/29/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190334707
Principal investigator 1 Genentech, Inc. $3,358.00 10/17/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571379
Principal investigator 1 Genentech, Inc. $5,658.00 10/10/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571383
Principal investigator 1 BeOne Medicines Ltd. $1,907.00 09/19/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327279
Principal investigator 1 Epizyme, Inc. $800.00 09/18/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285166
Principal investigator 1 BeOne Medicines Ltd. $750.00 08/20/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327101
Principal investigator 1 Genentech, Inc. $1,000.00 08/18/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571365
Principal investigator 1 Genentech, Inc. $682.00 08/18/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571375
Principal investigator 1 Genentech, Inc. $1,200.00 08/08/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571370
Principal investigator 1 BeOne Medicines Ltd. $2,556.00 08/01/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327039
Principal investigator 1 BeOne Medicines Ltd. $5,430.00 08/01/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327253
Principal investigator 1 BeOne Medicines Ltd. $2,347.00 08/01/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327261
Principal investigator 1 BeOne Medicines Ltd. $2,028.00 08/01/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327265
Principal investigator 1 Genentech, Inc. $6,345.00 07/29/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571362
Principal investigator 1 Genentech, Inc. $2,387.00 07/23/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571353
Principal investigator 1 Genentech, Inc. $700.00 07/15/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571306
Principal investigator 1 Genentech, Inc. $1,702.00 07/09/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571358
Principal investigator 1 BeOne Medicines Ltd. $59.00 06/25/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190326232
Principal investigator 1 BeOne Medicines Ltd. $1,600.00 06/25/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190331271
Principal investigator 1 BeOne Medicines Ltd. $1,380.00 06/25/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190338738
Principal investigator 1 BeOne Medicines Ltd. $1,907.00 06/13/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190326210
Principal investigator 1 Epizyme, Inc. $2,122.00 05/30/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285158
Principal investigator 1 Epizyme, Inc. $2,122.00 05/30/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285160
Principal investigator 1 Epizyme, Inc. $2,122.00 05/30/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285162
Principal investigator 1 Epizyme, Inc. $4,072.00 05/30/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285164
Principal investigator 1 Acerta Pharma LLC $7,394.18 05/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185542354
Principal investigator 1 Genentech, Inc. $19,385.00 05/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571315
Principal investigator 1 Genentech, Inc. $177.00 05/21/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571288
Principal investigator 1 BeiGene, Ltd. $1,000.00 05/16/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190322956
Principal investigator 1 Genentech, Inc. $47,896.00 05/14/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571340
Principal investigator 1 BeiGene, Ltd. $55.00 05/07/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190322952
Principal investigator 1 BeiGene, Ltd. $59.00 05/07/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190325632
Recipient F. Hoffmann-La Roche AG $407.86 04/28/2025 Covered Recipient Physician Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211535241
Recipient F. Hoffmann-La Roche AG $127.74 04/25/2025 Covered Recipient Physician Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211535237
Principal investigator 1 BeiGene, Ltd. $1,907.00 04/21/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190322870
Principal investigator 1 Genentech, Inc. $1,000.00 04/17/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571327
Principal investigator 1 Genentech, Inc. $2,319.00 04/09/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571336
Principal investigator 1 Genentech, Inc. $5,658.00 04/08/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571348
Principal investigator 1 Genentech, Inc. $27,255.00 04/03/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571345
Principal investigator 1 Genentech, Inc. $15,202.00 03/17/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571331
Principal investigator 1 Epizyme, Inc. $1,000.00 03/06/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285156
Principal investigator 1 Genentech, Inc. $700.00 02/19/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571292
Principal investigator 1 BeiGene, Ltd. $1,907.00 01/29/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190324648
Principal investigator 1 Genentech, Inc. $177.00 01/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571300
Principal investigator 1 Genentech, Inc. $1,000.00 01/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571303
Principal investigator 1 Genentech, Inc. $29,588.00 01/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571318
Principal investigator 1 Genentech, Inc. $842.00 01/28/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571323
Principal investigator 1 BeiGene, Ltd. $2,556.00 01/27/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190320006
Principal investigator 1 BeiGene, Ltd. $2,347.00 01/27/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190320080
Principal investigator 1 BeiGene, Ltd. $2,028.00 01/27/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190324656
Principal investigator 1 AstraZeneca UK Limited $55,027.69 01/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185542356
Principal investigator 1 Genentech, Inc. $177.00 01/21/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INST DBA AHN RESEARCH INSTITUTE
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211571295
Principal investigator 1 Epizyme, Inc. $8,316.00 01/17/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285150
Principal investigator 1 Epizyme, Inc. $800.00 01/06/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285152
Principal investigator 1 Epizyme, Inc. $800.00 01/06/2025 Non-covered Recipient Entity
Allegheny Singer Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285154